Top Page
Biotron
(Sydney:BIT)
Biotron (BIT) vs. iShares MSCI Australia ETF (EWA)
Biotron Business Overview & Revenue Model
Biotron Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.81M | 1.81M | 1.65M | 1.43M | 1.56M | 1.46M |
| Gross Profit | 1.81M | 1.81M | 1.65M | 1.39M | 1.51M | 1.41M |
| EBITDA | -333.81K | -333.81K | -5.04M | -4.88M | -2.73M | -4.56M |
| Net Income | -318.57K | -318.57K | -3.44M | -3.49M | -2.78M | -3.19M |
Balance Sheet | ||||||
| Total Assets | 980.40K | 980.40K | 493.48K | 4.14M | 1.91M | 4.33M |
| Cash, Cash Equivalents and Short-Term Investments | 931.68K | 931.68K | 393.20K | 3.98M | 1.74M | 4.21M |
| Total Debt | 0.00 | 0.00 | 7.13K | 45.27K | 77.24K | 6.35K |
| Total Liabilities | 428.51K | 428.51K | 737.51K | 962.49K | 813.57K | 463.51K |
| Stockholders Equity | 551.89K | 551.89K | -244.03K | 3.17M | 1.09M | 3.86M |
Cash Flow | ||||||
| Free Cash Flow | -568.87K | -568.87K | -3.57M | -3.29M | -2.44M | -3.41M |
| Operating Cash Flow | -565.80K | -565.80K | -3.57M | -3.29M | -2.44M | -3.41M |
| Investing Cash Flow | -3.07K | -3.07K | 0.00 | 0.00 | 0.00 | -5.72K |
| Financing Cash Flow | 1.11M | 1.11M | -22.62K | 5.53M | -33.17K | -36.96K |
Biotron Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$13.78M | -2.33 | -166.70% | ― | ― | ― | |
46 Neutral | AU$8.43M | -27.50 | -184.73% | ― | ― | 87.88% | |
46 Neutral | AU$9.15M | -2.54 | ― | ― | ― | ― | |
40 Underperform | AU$2.17M | -4.33 | -28.49% | ― | ― | 46.43% | |
39 Underperform | AU$6.95M | -3.89 | -289.05% | ― | ― | 24.09% | |
37 Underperform | AU$11.48M | -1.61 | -628.72% | ― | ― | 31.87% |
Biotron Corporate Events
Biotron Limited has notified the ASX of changes in directors’ interests in the company’s securities, in compliance with listing requirements for disclosure of director shareholdings. The filing shows chairman Michael J. Hoy increased his indirect holding via Umbiram Pty Limited
Biotron Limited has lodged an application with the ASX for quotation of 181,666,666 new options (ASX code: BITO) expiring on 24 November 2027, with an issue date of 19 December 2025. The move significantly increases the volume of listed options over the company’s securities and provides an additional instrument for investors to gain exposure to Biotron’s equity, potentially broadening its shareholder base and supporting future capital-raising flexibility.
Biotron Limited has withdrawn a previously lodged Appendix 3G notice relating to the issue, conversion or payment up of unquoted securities and will replace it with an Appendix 2A. The change indicates an administrative correction in how the company reports recent equity-related activity to the market, with no direct operational or strategic implications disclosed for shareholders or other stakeholders at this stage.
Biotron Limited has appointed experienced life sciences executive and board director Dr Paul Kasian as a Non-Executive Director, effective 23 December 2025. With more than three decades of leadership across biotechnology, diagnostics, therapeutics and asset management, including prior roles as chairman or executive chairman at several ASX-listed and private health-related companies and senior investment roles at HSBC, Kasian is expected to strengthen Biotron’s governance, strategic direction and business development capabilities, supporting the company’s growth and positioning within the biotech industry.
Biotron Limited has had its ordinary shares (trading under the ASX code BITO) reinstated to quotation on the Australian Securities Exchange following confirmation that the company has met ASX Listing Rule 2.5 requirements. The return to trading status restores liquidity and market access for Biotron shareholders and signals that the company has addressed the exchange’s compliance conditions, potentially improving investor confidence and enabling the company to pursue its strategic and capital markets objectives under normal trading conditions.
Biotron Limited has notified the Australian Securities Exchange of the issue of 181,666,666 unquoted options, exercisable by 24 November 2027. The large grant of deferred options signals a significant equity-based component in the company’s capital or incentive structure, which may dilute existing shareholders over time but could also align management or stakeholder interests with the company’s longer-term performance, depending on the options’ terms and recipients.
Biotron Limited has released details of its top 20 option holders and the distribution schedule for its newly listed options on the ASX, issued in connection with recent Appendixes 2A. The disclosure enhances transparency around the company’s capital structure and derivative securities, providing investors and the market with clearer insight into the ownership and distribution of its listed options, which may influence perceptions of liquidity and potential future equity conversion.
Biotron Limited has completed its non-renounceable rights issue, raising $645,861 through the issue of 215,286,751 fully paid ordinary shares and 107,643,345 options, which will trade on the ASX under the code BITO. The capital will fund toxicology studies and small-scale production of its HBV drug, support ongoing antiviral R&D, cover patent and commercialisation expenses across its portfolio, and provide working capital, while a remaining shortfall of $878,733 is backed by a subscription commitment from Peak Asset Management with the final date to issue shortfall shares set for 12 March 2026.
Biotron Limited’s securities under the code BITO have been suspended from quotation by ASX Limited due to compliance issues with Listing Rule 2.5. This suspension is specific to the BITO class and does not affect other securities of Biotron Limited, indicating a focused regulatory compliance matter.
Biotron Limited has announced the quotation of 33,333,333 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective December 10, 2025. This move is part of a previously announced transaction and is expected to enhance Biotron’s market presence and provide additional capital to support its ongoing research and development efforts.
Biotron Limited announced the quotation of 500,000,000 ordinary fully paid securities on the ASX, as part of a transaction previously disclosed. This move is likely to enhance the company’s financial flexibility and market presence, potentially impacting its operations and stakeholder interests positively.
Biotron Limited announced the issuance of 500,000 unquoted performance shares as part of a previously disclosed transaction. This move is expected to enhance the company’s operational capabilities and strengthen its position in the biotechnology sector, potentially benefiting stakeholders by advancing its antiviral therapy projects.
Biotron Limited has successfully completed the acquisition of Sedarex Limited, a move approved by its shareholders. This acquisition involves the issuance of 500 million consideration shares and 33,333,333 facilitation shares, with certain shares subject to voluntary escrow, indicating strategic growth and potential expansion in Biotron’s operations.
Biotron Limited has successfully completed Tranche 2 of its Placement, raising a total of $1 million to fund the development of products from its recent acquisition of Sedarex Limited. This acquisition and funding are pivotal for Biotron, as they enhance its product pipeline with a late-stage clinical asset and reinforce its commitment to antiviral research, positioning the company for future growth.
Biotron Limited announced the issuance of 15,000,000 unquoted equity securities as part of a previously announced transaction. This move could potentially impact the company’s financial structure and market positioning, as it may provide additional capital for ongoing research and development efforts, thereby influencing stakeholder interests and expectations.
Biotron Limited has announced the quotation of 134,246,669 fully paid ordinary securities on the Australian Securities Exchange (ASX) as part of previously announced transactions. This development is expected to enhance the company’s financial position and potentially improve its market visibility, thereby impacting its operations and industry positioning positively.
Biotron Limited has announced the dispatch of its prospectus and the opening of a non-renounceable entitlement offer, which was initially announced on October 15, 2025. The offer includes the issuance of attaching options and is aimed at eligible shareholders, with the rights issue set to close on December 12, 2025. This move is expected to provide investors with an opportunity to gain exposure to the company’s equities, potentially impacting its market positioning and stakeholder interests.
Biotron Limited has announced details regarding its rights issue, initially disclosed on 15 October 2025. The rights issue includes an offer of one attaching option for every two shares issued, with fractions of attaching options being rounded down. The prospectus related to this rights issue will be distributed to eligible shareholders around 27 November 2025, and they are advised to review it before acquiring securities.
Biotron held its Annual General Meeting where several key resolutions were voted on, including the adoption of the Remuneration Report and the re-election of directors Robert B. Thomas and Michael J. Medway. Additionally, Peter Scott and Hugh Milner were elected as new directors. These decisions are expected to impact the company’s governance and strategic direction, potentially influencing its market position and stakeholder relations.
Biotron faced a challenging year after its COVID-19 trial, BIT225-012, did not meet primary efficacy endpoints, highlighting the risks in late-stage drug development. Despite this setback, Biotron is pursuing growth and diversification through the proposed acquisition of Sedarex, which offers a late-stage clinical asset in next-generation general anesthesia and supports the continuation of Biotron’s anti-viral programs. The acquisition is seen as a strategic move to benefit shareholders and position the company for future development opportunities.
Biotron Limited has announced significant progress in its Hepatitis B Virus (HBV) program, highlighting the efficacy of its lead drug, BIT-HBV001. The drug has demonstrated superior anti-HBV activity compared to the current first-line treatment, Tenofovir, in both in vitro and in vivo studies. BIT-HBV001 not only reduced HBV DNA levels significantly but also showed potential in eradicating the virus by inhibiting cccDNA, a key differentiator from existing treatments. The company has filed a patent for its novel compounds, indicating a strategic move to strengthen its position in the antiviral drug market.
Biotron Limited’s Managing Director, Michelle Miller, presented a PowerPoint presentation to investors, which was announced via ASX. This presentation is part of Biotron’s ongoing efforts to engage with stakeholders and provide updates on its strategic initiatives, potentially impacting its market positioning and investor relations.
Biotron has announced a strategic acquisition of Sedarex Limited, which owns SedRx, a patented next-generation general anesthetic formulation. This acquisition is expected to significantly enhance Biotron’s growth and diversification prospects, offering substantial benefits to shareholders through value-adding milestones. SedRx, containing the active ingredient alfaxalone, has demonstrated superior safety and cognitive outcomes compared to the current market leader, propofol, and has potential for fast market entry through FDA and EMA pathways. The acquisition also opens opportunities for new indications in the neuroscientific field, providing Biotron with a largely de-risked asset and access to a large addressable market.
Biotron Limited has announced an upcoming investor webinar scheduled for November 11, 2025, where Managing Director Michelle Miller will discuss the company’s recent acquisition of Sedarex Limited. This strategic move is expected to enhance Biotron’s industry positioning by expanding its portfolio and potentially increasing its market share, which could have significant implications for stakeholders.
Biotron Limited has issued a supplementary notice for its upcoming Annual General Meeting, scheduled for November 17, 2025. The notice includes an additional resolution, known as the Spill Resolution, which could lead to an extraordinary general meeting if a significant portion of shareholders vote against the company’s Remuneration Report. This development highlights potential governance changes and underscores the importance of shareholder engagement in the company’s strategic decisions.
Biotron Limited has made significant strides in the quarter ending September 2025, focusing on the assessment of its lead Hepatitis B virus compound in animal models and advancing its commercialization efforts with C14 Consulting Group. The company announced the acquisition of Sedarex Limited, which holds patents for SedRx, a next-generation general anesthetic with improved safety and cognitive outcomes. This acquisition, pending shareholder approval, is supported by a $2.5 million capital raising and positions Biotron to expand into the neuroscientific field, potentially enhancing its market presence and offering new growth opportunities.
Biotron Limited has successfully issued 199,086,664 new fully paid ordinary shares at $0.003 per share, raising $597,260 before costs. This strategic move, executed under the company’s 15% capacity pursuant to ASX Listing Rule 7.1, allows for immediate trading of these shares, potentially enhancing Biotron’s financial flexibility and market presence.
Biotron Limited has announced the quotation of 199,086,664 fully paid ordinary securities on the Australian Securities Exchange (ASX) as part of previously announced transactions. This move is expected to enhance Biotron’s market presence and provide additional capital for ongoing and future projects, potentially strengthening its position in the biotechnology sector.
Biotron Limited has announced a proposed issue of 500,000 performance shares, with a planned issue date of November 24, 2025. This strategic move is part of the company’s efforts to enhance its market presence and operational capabilities, potentially impacting its industry positioning and offering opportunities for stakeholders.
Biotron Limited announced an update to its previous securities issuance plan, splitting the consideration shares into Ordinary Shares and Performance Shares. This strategic move is expected to enhance the company’s financial flexibility and potentially improve its market positioning, signaling a proactive approach to managing its capital structure and investor relations.
Biotron Limited has announced the acquisition of Sedarex Limited, with the consideration for the purchase consisting of 500 million ordinary Biotron shares and performance shares valued at $500,000. This acquisition is expected to enhance Biotron’s operational capabilities and strengthen its position in the pharmaceutical industry, particularly in the development of drugs for viral diseases. The announcement, authorized by the Managing Director, highlights the strategic move to expand Biotron’s portfolio and potential impact on stakeholders.
Biotron has released its Annual Report for the fiscal year ending June 30, 2025, along with the notice for its upcoming Annual General Meeting scheduled for November 17, 2025. This announcement is significant as it provides stakeholders with insights into the company’s financial health and strategic direction, potentially impacting investor confidence and market positioning.
Biotron Limited has announced the acquisition of Sedarex Limited and a capital raising initiative, which was detailed in an investor webinar led by Managing Director Michelle Miller. This strategic move is expected to enhance Biotron’s market position and expand its operational capabilities, potentially benefiting stakeholders by strengthening the company’s pipeline and financial standing.
Biotron Limited has announced a proposed issue of securities, comprising 166,666,666 options and 333,333,333 fully paid ordinary shares, with a planned issue date of November 24, 2025. This strategic move is likely aimed at raising capital to support the company’s ongoing research and development efforts, potentially enhancing its market position and providing value to stakeholders by advancing its antiviral therapeutics pipeline.
Biotron Limited has announced a proposed issue of 666,666,666 fully paid ordinary securities, scheduled for issuance on November 24, 2025. This move is expected to enhance the company’s capital base, potentially strengthening its market position and providing additional resources for ongoing research and development efforts, which could have significant implications for stakeholders and the company’s future growth.
Biotron Limited announced a proposed issue of 15 million new securities, with the issuance date set for November 24, 2025. This strategic move is expected to bolster the company’s financial position, potentially enhancing its capacity to advance ongoing projects and strengthen its market presence in the biotechnology sector.
Biotron Limited has announced a proposed issue of 33,333,333 fully paid ordinary securities, with the issuance date set for November 24, 2025. This move is part of a placement or other type of issue, which could potentially enhance the company’s capital base and support its ongoing research and development efforts in antiviral therapeutics.
Biotron Limited has announced a proposed issue of securities, including options and ordinary fully paid shares, as part of a standard pro rata issue. This move is expected to enhance the company’s financial flexibility and support its ongoing research and development efforts in antiviral therapies. The issuance is scheduled with an ex-date of November 20, 2025, and an issue date of December 19, 2025, indicating a strategic step to bolster its market position and potentially attract new investors.
Biotron Limited has announced the acquisition of Sedarex Limited, which holds global patents for SedRx, a safer next-generation general anaesthetic. This acquisition is supported by a $2.5 million capital raising initiative, led by Peak Asset Management. SedRx, which has shown superior safety and cognitive outcomes in clinical trials, is expected to transform Biotron’s operations by adding a late-stage clinical asset with new indications in the neuroscientific field. The acquisition is anticipated to enhance Biotron’s market positioning and offer significant benefits to its stakeholders.